| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Ann Thorac Surg 2002;74:164-169
© 2002 The Society of Thoracic Surgeons
a Department of Pulmonology, St. Antonius Hospital Nieuwegein, Nieuwegein, The Netherlands
b Department of Thoracic Surgery, St. Antonius Hospital Nieuwegein, Nieuwegein, The Netherlands
c department of Thoracic Surgery, University Medical Center Utrecht, Utrecht, The Netherlands
d department of Radiotherapy, University Medical Center Utrecht, Utrecht, The Netherlands
Accepted for publication March 28, 2002.
* Address reprint requests to Dr Schramel, Department of Pulmonology, St. Antonius Hospital, PO Box 2500, 3430 EM Nieuwegein, The Netherlands
e-mail: f.schramel{at}antonius.net
Background. The role of surgery after neoadjuvant chemotherapy in patients with stage IIIB non-small cell lung cancer (NSCLC) remains unclear.
Methods. A prospective multicenter trial of neoadjuvant chemotherapy followed by surgery or radiotherapy or both was conducted with 41 patients with stage IIIB NSCLC. End points were toxicity, response, downstaging, complete resectability, and survival. The diagnostic value of repeat mediastinoscopy after neoadjuvant chemotherapy (three courses of gemcitabine/cisplatin) was also studied.
Results. Response rate after neoadjuvant chemotherapy was 66% (27 of 41). Fifteen patients underwent repeat mediastinoscopy, which proved to be inadequate in 6 patients. Two repeat mediastinoscopies were false negative. Resection was performed in 18 patients, of which 10 proved to be radical. Hospital mortality was 2.4% (n = 1). Major complications occurred in 6 patients (fistula, empyema, hemorrhage). Histopathologically proven downstaging was seen in 16 patients (39%). Twenty-five patients underwent radiotherapy of whom 14 were diagnosed with stable/progressive disease and 9 with partial/complete response. Median survival for all patients was 15.1 months, for nonresponders 8.4 months and for responders 16.8 months (p = 0.11). Patients with partial/complete response had a mean survival of 21.5 months after resection and 13.0 months after radiotherapy (p = 0.0003).
Conclusions. Radical surgery can be performed in 37% (10 of 27) of the responders resulting in a prolonged survival. Surgery as part of combined modality treatment is feasible in stage IIIB NSCLC. Results of a repeat mediastinoscopy are disappointing and proved to be a not-so-effective restaging tool because of the high number of incomplete procedures and because it yields false negative results.
This article has been cited by other articles:
|
|
 |
|
  P. De Leyn and T. Lerut Reply to Van Schil and Stamatis Remediastinoscopy: a dangerous tool? Eur. J. Cardiothorac. Surg., September 1, 2008; 34(3): 708 - 709. [Full Text] [PDF]
|
|
|
|
 |
|
 F. J.F. Herth, J. T. Annema, R. Eberhardt, K. Yasufuku, A. Ernst, M. Krasnik, and R. C. Rintoul Endobronchial Ultrasound With Transbronchial Needle Aspiration for Restaging the Mediastinum in Lung Cancer J. Clin. Oncol., July 10, 2008; 26(20): 3346 - 3350. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. E. Van Schil and M. De Waele A second mediastinoscopy: how to decide and how to do it? Eur. J. Cardiothorac. Surg., April 1, 2008; 33(4): 703 - 706. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. De Leyn, D. Lardinois, P. E. Van Schil, R. Rami-Porta, B. Passlick, M. Zielinski, D. A. Waller, T. Lerut, and W. Weder ESTS guidelines for preoperative lymph node staging for non-small cell lung cancer Eur. J. Cardiothorac. Surg., July 1, 2007; 32(1): 1 - 8. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Granone, P. Van Schil, and A. Cesario Restaging patients with N2 (stage IIIa) non-small cell lung cancer after neoadjuvant chemoradiotherapy: A closer look at redo mediastinoscopy J. Thorac. Cardiovasc. Surg., January 1, 2007; 133(1): 275 - 276. [Full Text] [PDF]
|
|
|
|
|
|
P. De Leyn, S. Stroobants, W. De Wever, T. Lerut, W. Coosemans, G. Decker, P. Nafteux, D. Van Raemdonck, L. Mortelmans, K. Nackaerts, et al. Prospective Comparative Study of Integrated Positron Emission Tomography-Computed Tomography Scan Compared With Remediastinoscopy in the Assessment of Residual Mediastinal Lymph Node Disease After Induction Chemotherapy for Mediastinoscopy-Proven Stage IIIA-N2 Non-Small-Cell Lung Cancer: A Leuven Lung Cancer Group Study J. Clin. Oncol., July 20, 2006; 24(21): 3333 - 3339. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. J. Cerfolio, A. S. Bryant, and B. Ojha Restaging patients with N2 (stage IIIa) non-small cell lung cancer after neoadjuvant chemoradiotherapy: A prospective study J. Thorac. Cardiovasc. Surg., June 1, 2006; 131(6): 1229 - 1235. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Galetta, A. Cesario, S. Margaritora, V. Porziella, A. Piraino, R. M. D'Angelillo, M. A. Gambacorta, S. Ramella, L. Trodella, S. Valente, et al. Multimodality treatment of unresectable stage III non-small cell lung cancer: Interim analysis of a phase II trial with preoperative gemcitabine and concurrent radiotherapy J. Thorac. Cardiovasc. Surg., February 1, 2006; 131(2): 314 - 321. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Hellwig, T. P. Graeter, D. Ukena, T. Georg, C.-M. Kirsch, and H.-J. Schafers Value of F-18-fluorodeoxyglucose positron emission tomography after induction therapy of locally advanced bronchogenic carcinoma J. Thorac. Cardiovasc. Surg., December 1, 2004; 128(6): 892 - 899. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Ohno, T. Utsumi, Y. Sasaki, and Y. Suzuki Re-evaluation of non-palpable scalene lymph node biopsy for the staging of non-small cell lung cancer Eur. J. Cardiothorac. Surg., April 1, 2004; 25(4): 492 - 496. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Galetta, A. Cesario, S. Margaritora, V. Porziella, G. Macis, R. M. D'Angelillo, L. Trodella, S. Sterzi, and P. Granone Enduring challenge in the treatment of nonsmall cell lung cancer with clinical stage IIIB: results of a trimodality approach Ann. Thorac. Surg., December 1, 2003; 76(6): 1802 - 1809. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. C.M. Pitz, A. B. de la Riviere, H. A. van Swieten, C. J.J. Westermann, J.-W. J. Lammers, and J. M.M. van den Bosch Results of surgical treatment of T4 non-small cell lung cancer Eur. J. Cardiothorac. Surg., December 1, 2003; 24(6): 1013 - 1018. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. M. DeCamp, T. W. Rice, D. J. Adelstein, M. A. Chidel, L. A. Rybicki, S. C. Murthy, and E. H. Blackstone Value of accelerated multimodality therapy in stage IIIA and IIIB non-small cell lung cancer J. Thorac. Cardiovasc. Surg., July 1, 2003; 126(1): 17 - 25. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Danesi, F. De Braud, S. Fogli, T. M. De Pas, A. Di Paolo, G. Curigliano, and M. Del Tacca Pharmacogenetics of Anticancer Drug Sensitivity in Non-Small Cell Lung Cancer Pharmacol. Rev., March 1, 2003; 55(1): 57 - 103. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| ANN THORAC SURG | ASIAN CARDIOVASC THORAC ANN | EUR J CARDIOTHORAC SURG |
| J THORAC CARDIOVASC SURG | ICVTS | ALL CTSNet JOURNALS |
